Recurrence	Recurrence	NN	B-NP	O		0	10
of	of	IN	B-PP	O		11	13
Helicobacter pylori	Helicobacter_pylori	NNP	B-NP	O		14	33
infection	infection	NN	I-NP	O		34	43
1	1	CD	I-NP	O		44	45
year	year	NN	I-NP	O		46	50
after	after	IN	B-PP	O		51	56
successful	successful	JJ	B-NP	O		57	67
treatment	treatment	NN	I-NP	O		68	77
:	:	:	O	O		77	78
prospective	prospective	JJ	B-NP	O		79	90
cohort	cohort	JJ	I-NP	O		91	97
study	study	NN	I-NP	O		98	103
in	in	IN	B-PP	O		104	106
the	the	DT	B-NP	O		107	110
Republic	Republic	NNP	I-NP	O		111	119
of	of	IN	B-PP	O		120	122
Yemen	Yemen	NNP	B-NP	O		123	128
.	.	.	O	O		128	129

To	To	TO	B-VP	O		130	132
investigate	investigate	VB	I-VP	O		133	144
the	the	DT	B-NP	O		145	148
prevalence	prevalence	NN	I-NP	O		149	159
of	of	IN	B-PP	O		160	162
Helicobacter pylori	Helicobacter_pylori	NNP	B-NP	O		163	182
infection	infection	NN	I-NP	O		183	192
in	in	IN	B-PP	O		193	195
dyspeptic	dyspeptic	JJ	B-NP	O		196	205
patients	patient	NNS	I-NP	O		206	214
in	in	IN	B-PP	O		215	217
the	the	DT	B-NP	O		218	221
Republic	Republic	NNP	I-NP	O		222	230
of	of	IN	B-PP	O		231	233
Yemen	Yemen	NNP	B-NP	O		234	239
and	and	CC	O	O		240	243
the	the	DT	B-NP	O		244	247
recurrence	recurrence	NN	I-NP	O		248	258
rate	rate	NN	I-NP	O		259	263
1	1	CD	I-NP	O		264	265
year	year	NN	I-NP	O		266	270
after	after	IN	B-PP	O		271	276
apparently	apparently	RB	B-NP	O		277	287
successful	successful	JJ	I-NP	O		288	298
eradication	eradication	NN	I-NP	O		299	310
.	.	.	O	O		310	311

A	A	DT	B-NP	O		312	313
total	total	NN	I-NP	O		314	319
of	of	IN	B-PP	O		320	322
275	275	CD	B-NP	O		323	326
patients	patient	NNS	I-NP	O		327	335
with	with	IN	B-PP	O		336	340
chronic	chronic	JJ	B-NP	O		341	348
dyspepsia	dyspepsia	NN	I-NP	O		349	358
seen	see	VBN	B-VP	O		359	363
in	in	IN	B-PP	O		364	366
one	one	CD	B-NP	O		367	370
clinic	clinic	NN	I-NP	O		371	377
were	be	VBD	B-VP	O		378	382
enrolled	enrol	VBN	I-VP	O		383	391
.	.	.	O	O		391	392

Gastric	Gastric	JJ	B-NP	O		393	400
biopsies	biopsy	NNS	I-NP	O		401	409
were	be	VBD	B-VP	O		410	414
obtained	obtain	VBN	I-VP	O		415	423
at	at	IN	B-PP	O		424	426
endoscopy	endoscopy	NN	B-NP	O		427	436
and	and	CC	I-NP	O		437	440
H. pylori	H._pylori	NN	I-NP	O		441	450
infection	infection	NN	I-NP	O		451	460
was	be	VBD	B-VP	O		461	464
diagnosed	diagnose	VBN	I-VP	O		465	474
using	use	VBG	B-VP	O		475	480
the	the	DT	B-NP	O		481	484
rapid	rapid	JJ	I-NP	O		485	490
urease	urease	NN	I-NP	O		491	497
test	test	NN	I-NP	O		498	502
.	.	.	O	O		502	503

Patients	Patient	NNS	B-NP	O		504	512
with	with	IN	B-PP	O		513	517
H. pylori	H._pylori	NN	B-NP	O		518	527
infection	infection	NN	I-NP	O		528	537
were	be	VBD	B-VP	O		538	542
given	give	VBN	I-VP	O		543	548
either	either	CC	O	O		549	555
clarithromycin	clarithromycin	NN	B-NP	O		556	570
or	or	CC	I-NP	O		571	573
metronidazole	metronidazole	NN	I-NP	O		574	587
-	-	HYPH	B-VP	O		587	588
based	base	VBN	B-NP	O		588	593
triple	triple	JJ	I-NP	O		594	600
therapy	therapy	NN	I-NP	O		601	608
.	.	.	O	O		608	609

Six	Six	CD	B-NP	O		610	613
weeks	week	NNS	I-NP	O		614	619
later	later	RB	B-ADVP	O		620	625
H. pylori	H._pylori	NNP	B-NP	O		626	635
status	status	NN	I-NP	O		636	642
was	be	VBD	B-VP	O		643	646
assessed	assess	VBN	I-VP	O		647	655
using	use	VBG	B-VP	O		656	661
the	the	DT	B-NP	O		662	665
C-urea	C-urea	NN	I-NP	O		666	672
breath	breath	NN	I-NP	O		673	679
test	test	NN	I-NP	O		680	684
(	(	(	O	O		685	686
C-UBT	C-UBT	NN	B-NP	O		686	691
)	)	)	O	O		691	692
.	.	.	O	O		692	693

Those	Those	DT	B-NP	O		694	699
who	who	WP	B-NP	O		700	703
were	be	VBD	B-VP	O		704	708
negative	negative	JJ	B-ADJP	O		709	717
for	for	IN	B-SBAR	O		718	721
H. pylori	H._pylori	NNP	B-NP	O		722	731
had	have	VBD	B-VP	O		732	735
a	a	DT	B-NP	O		736	737
further	further	JJ	I-NP	O		738	745
C-UBT	C-UBT	NN	I-NP	O		746	751
after	after	IN	B-PP	O		752	757
1	1	CD	B-NP	O		758	759
year	year	NN	I-NP	O		760	764
to	to	TO	B-VP	O		765	767
establish	establish	VB	I-VP	O		768	777
the	the	DT	B-NP	O		778	781
recurrence	recurrence	NN	I-NP	O		782	792
rate	rate	NN	I-NP	O		793	797
.	.	.	O	O		797	798

The	The	DT	B-NP	O		799	802
prevalence	prevalence	NN	I-NP	O		803	813
of	of	IN	B-PP	O		814	816
H. pylori	H._pylori	NN	B-NP	O		817	826
infection	infection	NN	I-NP	O		827	836
at	at	IN	B-PP	O		837	839
entry	entry	NN	B-NP	O		840	845
to	to	TO	B-PP	O		846	848
the	the	DT	B-NP	O		849	852
study	study	NN	I-NP	O		853	858
was	be	VBD	B-VP	O		859	862
82.2	82.2	CD	B-NP	O		863	867
%	%	NN	I-NP	O		867	868
[	[	(	O	O		869	870
95%	95%	CD	B-NP	O		870	873
confidence	confidence	NN	I-NP	O		874	884
interval	interval	NN	I-NP	O		885	893
(	(	(	O	O		894	895
CI	CI	NN	B-NP	O		895	897
)	)	)	O	O		897	898
78-87	78-87	CD	B-NP	O		899	904
%	%	NN	I-NP	O		904	905
]	]	)	O	O		905	906
.	.	.	O	O		906	907

The	The	DT	B-NP	O		908	911
overall	overall	JJ	I-NP	O		912	919
eradication	eradication	NN	I-NP	O		920	931
rate	rate	NN	I-NP	O		932	936
6	6	CD	B-NP	O		937	938
weeks	week	NNS	I-NP	O		939	944
after	after	IN	B-SBAR	O		945	950
treatment	treatment	NN	B-NP	O		951	960
was	be	VBD	B-VP	O		961	964
49.1	49.1	CD	B-NP	O		965	969
%	%	NN	I-NP	O		969	970
(	(	(	O	O		971	972
95%	95%	CD	B-NP	O		972	975
CI	CI	NN	I-NP	O		976	978
42.6-55.6	42.6-55.6	CD	B-NP	O		979	988
%	%	NN	I-NP	O		988	989
)	)	)	O	O		989	990
by	by	IN	B-PP	O		991	993
intention-to	intention-to	AFX	B-NP	B-protein		994	1006
-	-	HYPH	I-NP	O		1006	1007
treat	treat	NN	I-NP	O		1007	1012
analysis	analysis	NN	I-NP	O		1013	1021
,	,	,	O	O		1021	1022
and	and	CC	O	O		1023	1026
60%	60%	CD	B-NP	O		1027	1030
(	(	(	O	O		1031	1032
95%	95%	CD	B-NP	O		1032	1035
CI	CI	NN	I-NP	O		1036	1038
53-67	53-67	CD	B-NP	O		1039	1044
%	%	NN	I-NP	O		1044	1045
)	)	)	O	O		1045	1046
by	by	IN	B-PP	O		1047	1049
per-protocol	per-protocol	JJ	B-NP	O		1050	1062
analysis	analysis	NN	I-NP	O		1063	1071
.	.	.	O	O		1071	1072

Recurrence	Recurrence	NN	B-NP	O		1073	1083
rate	rate	NN	I-NP	O		1084	1088
of	of	IN	B-PP	O		1089	1091
H. pylori	H._pylori	NN	B-NP	O		1092	1101
infection	infection	NN	I-NP	O		1102	1111
at	at	IN	B-PP	O		1112	1114
1	1	CD	B-NP	O		1115	1116
year	year	NN	I-NP	O		1117	1121
was	be	VBD	B-VP	O		1122	1125
34%	34%	CD	B-NP	O		1126	1129
(	(	(	O	O		1130	1131
95%	95%	CD	B-NP	O		1131	1134
CI	CI	NN	I-NP	O		1135	1137
14-45	14-45	CD	B-NP	O		1138	1143
%	%	NN	I-NP	O		1143	1144
)	)	)	O	O		1144	1145
and	and	CC	O	O		1146	1149
the	the	DT	B-NP	O		1150	1153
only	only	JJ	I-NP	O		1154	1158
predictor	predictor	NN	I-NP	O		1159	1168
of	of	IN	B-PP	O		1169	1171
recurrence	recurrence	NN	B-NP	O		1172	1182
was	be	VBD	B-VP	O		1183	1186
an	an	DT	B-NP	O		1187	1189
excess	excess	JJ	I-NP	O		1190	1196
delta	delta	NN	I-NP	O		1197	1202
C-UBT	C-UBT	NN	I-NP	O		1203	1208
value	value	NN	I-NP	O		1209	1214
less	less	JJR	B-ADJP	O		1215	1219
than	than	IN	B-PP	O		1220	1224
3.5	3.5	CD	B-NP	O		1225	1228
per	per	IN	B-PP	O		1229	1232
million	million	CD	B-NP	O		1233	1240
but	but	CC	O	O		1241	1244
equal	equal	JJ	B-ADJP	O		1245	1250
to	to	TO	B-PP	O		1251	1253
or	or	CC	O	O		1254	1256
greater	great	JJR	B-ADJP	O		1257	1264
than	than	IN	B-PP	O		1265	1269
2.5	2.5	CD	B-NP	O		1270	1273
per	per	IN	B-PP	O		1274	1277
million	million	CD	B-NP	O		1278	1285
at	at	IN	B-PP	O		1286	1288
6	6	CD	B-NP	O		1289	1290
weeks	week	NNS	I-NP	O		1291	1296
after	after	IN	B-PP	O		1297	1302
treatment	treatment	NN	B-NP	O		1303	1312
(	(	(	O	O		1313	1314
odds	odd	NNS	B-NP	O		1314	1318
ratio	ratio	NN	B-NP	O		1319	1324
2.28	2.28	CD	I-NP	O		1325	1329
;	;	:	O	O		1329	1330
95%	95%	CD	B-NP	O		1331	1334
CI	CI	NN	I-NP	O		1335	1337
1.17-4.44	1.17-4.44	CD	B-NP	O		1338	1347
;	;	:	O	O		1347	1348
P	P	NN	B-NP	O		1349	1350
=	=	SYM	B-VP	O		1351	1352
0.028	0.028	CD	B-NP	O		1353	1358
)	)	)	O	O		1358	1359
.	.	.	O	O		1359	1360

The	The	DT	B-NP	O		1361	1364
prevalence	prevalence	NN	I-NP	O		1365	1375
of	of	IN	B-PP	O		1376	1378
H. pylori	H._pylori	NN	B-NP	O		1379	1388
infection	infection	NN	I-NP	O		1389	1398
in	in	IN	B-PP	O		1399	1401
dyspeptic	dyspeptic	JJ	B-NP	O		1402	1411
patients	patient	NNS	I-NP	O		1412	1420
in	in	IN	B-PP	O		1421	1423
Yemen	Yemen	NN	B-NP	O		1424	1429
is	be	VBZ	B-VP	O		1430	1432
very	very	RB	B-ADJP	O		1433	1437
high	high	JJ	I-ADJP	O		1438	1442
,	,	,	O	O		1442	1443
the	the	DT	B-NP	O		1444	1447
eradication	eradication	NN	I-NP	O		1448	1459
rate	rate	NN	I-NP	O		1460	1464
with	with	IN	B-PP	O		1465	1469
standard	standard	JJ	B-NP	O		1470	1478
triple	triple	JJ	I-NP	O		1479	1485
therapy	therapy	NN	I-NP	O		1486	1493
was	be	VBD	B-VP	O		1494	1497
unsatisfactory	unsatisfactory	JJ	B-ADJP	O		1498	1512
probably	probably	RB	B-ADVP	O		1513	1521
because	because	IN	B-PP	O		1522	1529
of	of	IN	I-PP	O		1530	1532
widespread	widespread	JJ	B-NP	O		1533	1543
bacterial	bacterial	JJ	I-NP	O		1544	1553
resistance	resistance	NN	I-NP	O		1554	1564
due	due	JJ	B-PP	O		1565	1568
to	to	TO	B-PP	O		1569	1571
unrestricted	unrestricted	JJ	B-NP	O		1572	1584
antibiotic	antibiotic	JJ	I-NP	O		1585	1595
use	use	NN	I-NP	O		1596	1599
.	.	.	O	O		1599	1600

The	The	DT	B-NP	O		1601	1604
recurrence	recurrence	NN	I-NP	O		1605	1615
rate	rate	NN	I-NP	O		1616	1620
of	of	IN	B-PP	O		1621	1623
infection	infection	NN	B-NP	O		1624	1633
at	at	IN	B-PP	O		1634	1636
1	1	CD	B-NP	O		1637	1638
year	year	NN	I-NP	O		1639	1643
was	be	VBD	B-VP	O		1644	1647
high	high	JJ	B-ADJP	O		1648	1652
,	,	,	O	O		1652	1653
as	as	IN	B-PP	O		1654	1656
a	a	DT	B-NP	O		1657	1658
result	result	NN	I-NP	O		1659	1665
of	of	IN	B-PP	O		1666	1668
recrudescence	recrudescence	NN	B-NP	O		1669	1682
of	of	IN	B-PP	O		1683	1685
incompletely	incompletely	RB	B-NP	O		1686	1698
eradicated	eradicate	VBN	I-NP	O		1699	1709
organisms	organism	NNS	I-NP	O		1710	1719
rather	rather	RB	B-PP	O		1720	1726
than	than	IN	I-PP	O		1727	1731
reinfection	reinfection	NN	B-NP	O		1732	1743
.	.	.	O	O		1743	1744

